It is unclear to many providers how updated cervical cancer screening guidelines and new ACA preventative care initiatives will impact clinical practice. To address this, AHRP recently convened a panel of experts to develop consensus on key issues relating to this topic and developed a comprehensive consensus report. Key points of the report include:
1. The impact of the ACA on access to screening services
2. Clinical education and training for primary care providers on the latest prevention recommendations
3. The standards for ...
Three-page news brief by Cervical Cancer Action provides guidance on use of HPV vaccine in areas with high HIV prevalence. Key messages include:
HPV infection doubles the risk of acquiring HIV in women and men. HIV also significantly increases the risk of persistent HPV infections, which can lead to cervical cancer. Studies show that HIV-infected women have the ability to mount the necessary immune response to HPV antigens—that is, they have the biological capacity to benefit from the vaccine. The potential benefit of ...
New WHO document provides assessments of social mobilization and communication of HPV vaccine implementation in Latvia, Malaysia, and Rwanda in 2012 to understand the issues and solutions in different socioeconomic, cultural, religious, and regional settings. Discusses lessons learned a 2-day gathering to review HPV vaccine social mobilization and communication issues with both communications and new vaccine focal points in late February 2013. From the regions, they have multiple experiences from other countries (Bhutan, Mongolia, Romania, U.S., India, Pacific Island countries, etc.) ...
Recent article by Kristen Forbes from the EVE foundation on when to get screened, including what age, how often, and for how long. Also details how to prepare for your pap test and how long it takes to get your results.
One Dose of HPV Vaccine May be Enough to Prevent Cervical Cancer
PHILADELPHIA — Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer ...
Safety assured of HPV vaccine—The Committee reviewed updated information about the safety of human papillomavirus vaccines (HPV). The last review was conducted in June 2009, * and GACVS noted at the time that accumulating evidence on the safety of HPV vaccines was reassuring and that studies on HPV immunization had been initiated, along with capacity-building for adverse events monitoring. GACVS continues to place a high priority on the ongoing collection of high-quality safety data in settings where the vaccine is ...
For decades the annual Pap test was women’s chief protection against cervical cancer. That all changed when a test for human papillomavirus, the cause of most cervical cancer, was approved in 2003.
With the HPV test, women don’t need to get Pap tests as often. But that message hasn’t gotten through to many doctors.
Just 39 percent of clinicians ordered HPV tests for women when they went in for a checkup in five Michigan clinics, researchers found. Other doctors were ordering the ...
According to Ob.Gyn. News,
An investigational 9-valent human papillomavirus vaccine could prevent up to 85% of invasive cervical cancer, according to a spokesman for Merck, the company developing the product.
The vaccine (V503) adds five new HPV strains to the four already included in the current quadrivalent vaccine. The addition of HPV strains 31/33/45/52/58 should protect against the 30% of cervical cancers that are not caused by HPV 16 and 18, Dr Alain Luxembourg said at a meeting of the Centers for ...
Our free medical care program is an annual CSR activity by the church. This year we are focusing on cervical cancer.
Find below a copy of the publication for the event.
We will be offering free cervical cancer
Date: Sunday November 10, 2013
Time: 8am – 1pm
Venue: R.C.C.G House of Grace
His Grace Multipurpose Hall
127 / 129 Idimu Road, Field Bus stop, Ejigbo Lagos.
(Adjacent to Dapsey Petrol Station)
An investigational 9-valent human papillomavirus vaccine could prevent up to 85 percent of invasive cervical cancer, according to a spokesman for Merck, the company developing the product. The vaccine adds five new HPV strains to the four already included in the current quadrivalent vaccine. The addition of HPV strains 31/33/45/52/58 should protect against the 30% of cervical cancers that are not caused by HPV 16 and 18, Dr Alain Luxembourg said at a meeting of the Centers for Disease Control ...